Sarepta announces positive expression and functional data from srp-9003 gene therapy trial

Sarepta therapeutics announces positive expression and functional data from the srp-9003 gene therapy trial to treat limb-girdle muscular dystrophy type 2e.sarepta therapeutics inc - a mean signal intensity of 73% in high-dose group was observed compared to normal control.sarepta therapeutics inc - an 89% mean reduction of creatine kinase (ck) from baseline was observed in high-dose cohort.
SRPT Ratings Summary
SRPT Quant Ranking